Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Identifying drug-drug interactions (DDIs) is essential to prevent adverse effects from polypharmacy. Although deep learning has advanced DDI identification, the gap between powerful models and their lack of clinical application and evaluation has hindered clinical benefits. Here, we developed a Multi-Dimensional Feature Fusion model named MDFF, which integrates one-dimensional simplified molecular input line entry system sequence features, two-dimensional molecular graph features, and three-dimensional geometric features to enhance drug representations for predicting DDIs. MDFF was trained and validated on two DDI datasets, evaluated across three distinct scenarios, and compared with advanced DDI prediction models using accuracy, precision, recall, area under the curve, and F1 score metrics. MDFF achieved state-of-the-art performance across all metrics. Ablation experiments showed that integrating multi-dimensional drug features yielded the best results. More importantly, we obtained adverse drug reaction reports uploaded by Xiangya Hospital of Central South University from 2021 to 2023 and used MDFF to identify potential adverse DDIs. Among 12 real-world adverse drug reaction reports, the predictions of 9 reports were supported by relevant evidence. Additionally, MDFF demonstrated the ability to explain adverse DDI mechanisms, providing insights into the mechanisms behind one specific report and highlighting its potential to assist practitioners in improving medical practice.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12268060PMC
http://dx.doi.org/10.1016/j.jpha.2025.101194DOI Listing

Publication Analysis

Top Keywords

drug-drug interactions
8
deep learning
8
advanced ddi
8
adverse drug
8
drug reaction
8
reaction reports
8
adverse
5
mdff
5
identify drug-drug
4
interactions deep
4

Similar Publications

Preface to DMR drug-drug interactions special issue.

Drug Metab Rev

August 2025

Pharmacokinetics, Dynamics, Metabolism and Bioanalytics, Merck & Co., Inc, Boston, MA, USA.

View Article and Find Full Text PDF

Background: The COVID-19 antiviral Nirmatrelvir/Ritonavir (Paxlovid, N/R) was approved for use in Canada in January 2022, with the Government of Canada assuming a procurement role and provinces, territories, and federal departments implementing usage within their respective healthcare systems. The objective of this analysis is to describe how N/R was implemented across various jurisdictions in the first six months after it was available for use and identify promising implementation practices.

Methods: Fourteen semi-structured discussions in small group settings were conducted with jurisdictional representatives involved in the implementation of N/R.

View Article and Find Full Text PDF

Motivation: The increasing demand for effective drug combinations has made drug-drug interaction prediction a critical task in modern pharmacology. While most existing research focuses on small-molecule drugs, the role of biotech drugs in complex disease treatments remains relatively unexplored. Biotech drugs, derived from biological sources, have unique molecular structures that differ significantly from those of small molecules, making their interactions more challenging to predict.

View Article and Find Full Text PDF

Background: Membrane transport proteins are critical determinants of systemic and intracellular drug levels, thereby contributing substantially to drug response and/or adverse drug reactions. Therefore, the U.S.

View Article and Find Full Text PDF

Background: Omeprazole, a widely used proton pump inhibitor, has been associated with rare but serious adverse events such as myopathy. Previous research suggests that concurrent use of omeprazole with fluconazole, a potent cytochrome P450 (CYP) 2C19/3A4 inhibitor, may increase the risk of myopathy. However, the contribution of genetic polymorphisms in CYP enzymes remains unclear.

View Article and Find Full Text PDF